重大事件
即時報告
8-K
2026-06-30
Estrella Immunopharma股東會通過委任Macias Gini & O'Connell LLP為核數師 贊成票逾3035萬
AI 繁中摘要
Estrella Immunopharma, Inc.（ESLA）於2026年6月29日以虛擬形式舉行2025/2026年度股東大會，就一項議案進行表決。
截至記錄日2026年5月20日，公司已發行並有投票權的普通股共43,034,228股，出席或委派代表的股份為30,351,608股，約佔70.5%，達到法定人數。
會上唯一議案為「批准委任Macias Gini & O’Connell LLP為截至2026年12月31日止財政年度的獨立註冊會計師事務所」。投票結果：贊成30,351,203票、反對400票、棄權5票，無經紀人非投票。該議案獲得通過。
股東對核數師任命給予壓倒性支持，反映公司治理獲肯定，短期內無重大財務報表審計風險。投資者可留意公司後續業績披露及研發進展。📋✅
展開英文正文
false 0001844417 0001844417 2026-06-29 2026-06-29 0001844417 ESLA:CommonStockParValue0.0001PerShareMember 2026-06-29 2026-06-29 0001844417 ESLA:WarrantsEachWholeWarrantExercisableForOneShareOfCommonStockMember 2026-06-29 2026-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2026 Estrella Immunopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40608 86-1314502 (State or other jurisdiction (Commission File Number) (IRS Employer of incorporation) Identification Number) 5858 Horton Street, Suite 370 Emeryville, California 94608 (Address of principal executive offices) (Zip Code) (510) 318-9098 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act. Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.0001 per share ESLA The Nasdaq Stock Market LLC Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 ESLAW The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.07. Submission of Matters to a Vote of Security Holders. Estrella Immunopharma, Inc. (the “Company”) held its Combined 2025/2026 Annual Meeting of Stockholders (the “Annual Meeting”) on June 29, 2026, at 10:00 a.m. Eastern Time by means of remote communication, in a virtual-only format, via live audio webcast. As of the close of business on May 20, 2026, the record date for the Annual Meeting, there were 43,034,228 shares of the Company’s common stock outstanding and entitled to vote. Holders of 30,351,608 shares of common stock were present or represented by proxy at the Annual Meeting, constituting approximately 70.5% of the shares of common stock outstanding and entitled to vote and a quorum for the transaction of business. One proposal was submitted to a vote of the Company’s stockholders at the Annual Meeting. The proposal is described in detail in the Company’s definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on May 27, 2026. The final voting results are set forth below. Proposal 1— Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment of Macias Gini & O’Connell LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results were as follows: For Against Abstain Broker Non-Votes 30,351,203 400 5 0 There were no broker non-votes with respect to Proposal 1. Based on the final voting results, Proposal 1 was approved. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Estrella Immunopharma, Inc. By: /s/ Peter Xu Name: Peter Xu Title: Chief Financial Officer Date: June 30, 2026